Recent 8-K filings for DMAA

• May 5, 2026, 7:59 PM ET M&A materiality 0.90 neutral item 1.01item 9.01 ◈ Material Agreements ×3

  DMAA SPAC signs $1B deal to merge with AI/analytics firm Power Analytics Global

  Definitive merger agreement with Power Analytics Global (PAGC) at target enterprise value of $1.0B; floor of $300M.

• May 1, 2026, 7:59 PM ET other material materiality 0.85 neutral item 5.03item 5.07item 8.01item 9.01 ◈ Governance Changes◈ Shareholder Votes

  SPAC DMAA shareholders approve extension to April 2027; ~28% of shares redeemed for $99.3M

  Extension proposal approved: 18,906,281 for, 4,892,646 against, 0 abstain.

• April 8, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 8.01item 9.01

  DMAA signs LOI for de-SPAC merger with Power Analytics Global Corp at ~$1B valuation

  Non-binding letter of intent signed April 7, 2026, with target Power Analytics Global Corp (Delaware).

• March 6, 2026, 6:59 PM ET leadership materiality 0.70 negative item 5.02

  CEO Lynn Stockwell resigns after affiliate fund irregularities; Roger Bendelac appointed CEO

  Lynn Stockwell resigned as CEO, Executive Chair, and Board member of DMAA and affiliate, effective Feb 28, 2026.

• February 4, 2025, 6:59 PM ET other material materiality 0.65 neutral item 8.01item 9.01

  Drugs Made In America Acquisition Corp. closes $200M IPO and $4M private placement

  IPO of 20,000,000 units at $10.00 each raises $200,000,000 gross proceeds.

• January 30, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 5.03item 8.01item 9.01 ◈ Governance Changes

  Drugs Made In America Acquisition Corp. closes $200M IPO, deposits $201M in trust

  Closed IPO of 20,000,000 units at $10.00 per unit for gross proceeds of $200 million.

Materiality & sentiment trend

Max materiality 0.90 · Median 0.57 · Most common event other_material

1 positive 2 negative 9 neutral

source · DMAA on sec.gov